Nanodrug modified with engineered cell membrane targets CDKs to activate aPD-L1 immunotherapy against liver metastasis of immune-desert colon cancer
Authors:
- 3 April 2024
- journal article
- research article
- Published by Elsevier in Journal of Controlled Release
- Vol. 369, 309-324
Abstract
No abstract availableKeywords
Funding Information
- China Postdoctoral Science Foundation
This publication has 39 references indexed in Scilit:
- Association of PD-L1 Expression and Other Variables With Benefit From Immune Checkpoint Inhibition in Advanced Gastroesophageal CancerJAMA Oncology, 2022
- Organoid Modeling of the Tumor Immune MicroenvironmentCell, 2018
- Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cellsNature, 2016
- Cancer‐Cell‐Biomimetic Nanoparticles for Targeted Therapy of Homotypic TumorsAdvanced Materials, 2016
- Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 BlockadeCancer Cell, 2016
- Development and function of human innate immune cells in a humanized mouse modelNature Biotechnology, 2014
- Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trialThe Lancet Oncology, 2013
- The Role of Cdk5 in Neuroendocrine Thyroid CancerCancer Cell, 2013
- Oncology Meets Immunology: The Cancer-Immunity CycleImmunity, 2013
- Cdk1 is sufficient to drive the mammalian cell cycleNature, 2007